N-terminal pro-brain natriuretic peptide and electrocardiographic variables associated with increased risk of complete atrioventricular block and mortality in patients with acute inferior myocardial infarction

Basit Öğe Kaydı
dc.authoridözdemir, özcan/0000-0001-8459-320X
dc.authoridOsmonov, Damirbek/0000-0003-2538-6192
dc.authorwosidözdemir, özcan/AAZ-3242-2021
dc.authorwosidOsmonov, Damirbek/M-6828-2018
dc.contributor.authorGeyik, Bilal
dc.contributor.authorOzdemir, Ozcan
dc.contributor.authorOsmonov, Damirbek
dc.contributor.authorSoylu, Mustafa Ozcan
dc.date.accessioned2024-06-12T10:58:12Z
dc.date.available2024-06-12T10:58:12Z
dc.date.issued2012
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Although brain natriuretic peptide (BNP) levels are shown to be an important prognostic factor in patients with acute myocardial infarction (MI), the relationship between arrhythmias and BNP levels in not known. This study assessed whether baseline clinical factors, N-terminal-proBNP (NT-proBNP) levels and electrocardiographic patterns of acute inferior MI are associated with greater risk of developing complete atrioventricular block (CAVB) and mortality. Methods and Results: Seventy-nine consecutive patients (52 male, 27 females with an average age of 64.2 +/- 10.9 years) with CAVB and 119 control patients (93 male, 16 female with an average age of 57.7 +/- 11.4 years) without CAVB were enrolled. Regression analysis revealed that NT-proBNP levels > 104 pg/mL increased the development of CAVB by 10.1 folds but the thrombolytice therapy decresed the development of CAVB by 2.8 folds. NT-proBNP > 92 pg/mL increased the mortality by 8.9 folds, a ratio of ST-segment elevation in lead III:II > 1 by 3.1 folds, ST segment elevation > 1 mm in RV4 by 3.5 folds, ejection fraction < 35% by 24.2 folds, age > 65 years by 8.3 folds and CAVB by 6.8 folds, on contrary thrombolytic treatment decreased the morality by 3.3 folds. Conclusion: Simple electrocardiographic measurements and NT-proBNP levels at admission can be used as a screening test for development of complications such as CAVB, right ventricular involvement and mortality during acute inferior wall MI. (Cardiol J 2012; 19, 5: 479-489)en_US
dc.identifier.doi10.5603/CJ.2012.0088
dc.identifier.endpage486en_US
dc.identifier.issn1897-5593
dc.identifier.issue5en_US
dc.identifier.pmid23042311en_US
dc.identifier.scopus2-s2.0-84867529920en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage479en_US
dc.identifier.urihttps://doi.org/10.5603/CJ.2012.0088
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19979
dc.identifier.volume19en_US
dc.identifier.wosWOS:000311771900007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofCardiology Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectComplete Atrioventricular Blocken_US
dc.subjectST-Segment Elevation Inferior Myocardial Infarctionen_US
dc.subjectBrain Natriuretic Peptideen_US
dc.subjectRight-Ventricular Involvementen_US
dc.subjectAcute Coronary Syndromesen_US
dc.subjectSt-Segment Elevationen_US
dc.subjectComplete Heart-Blocken_US
dc.subjectThrombolytic Therapyen_US
dc.subjectPrognostic-Significanceen_US
dc.subjectAtrial-Fibrillationen_US
dc.subjectPlasma-Levelsen_US
dc.subjectLead-Iien_US
dc.subjectArteryen_US
dc.titleN-terminal pro-brain natriuretic peptide and electrocardiographic variables associated with increased risk of complete atrioventricular block and mortality in patients with acute inferior myocardial infarctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu